ClinicalTrials.gg
CompletedNCT04308681Updated Feb 3, 2026Results posted

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

A Phase 2 interventional study of BMS-986278 Placebo and BMS-986278 in Pulmonary Fibrosis, sponsored by Bristol-Myers Squibb. Completed at 119 sites in 18 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
403
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 128 studies in Pulmonary Fibrosis with a site in United States — 30 open to participants now, 42 under way, 5 of them phase 3. Pulmonary Fibrosis · United States.

Enrollment
10th of 90
403 · median 50
Started
2020
with 8 others
Phase 2
43 of 128
9 open now
Registered
81st of 128
by date
Lead sponsor
4 of 128
Bristol-Myers Squibb

Among the 128 studies in Pulmonary Fibrosis with a site in United States, this one is the 10th largest by enrollment of the 90 interventional ones that give a count, is one of 9 that started in 2020, is one of 43 in phase 2, and was the 81st registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

30 of the 128 studies in Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.

03

Conditions studied

  • Pulmonary Fibrosis

Keywords

  • Idiopathic pulmonary fibrosis
  • Progressive Fibrotic Interstitial Lung Disease
  • Idiopathic interstitial pneumonia
  • Fibrotic interstitial pneumonia
  • Fibrotic interstitial lung disease
  • Fibrosing interstitial lung disease
  • Interstitial lung disease
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For the idiopathic pulmonary fibrosis (IPF) Cohort

  • Diagnosis of IPF within 7 years of screening
  • Female and males ≥ 40 years of age

For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort

  • Evidence of progressive ILD within the 24 months before screening
  • Female and male ≥ 21 years of age.

Exclusion criteria

Exclusion Criteria:

  • Women of (WOCBP)
  • Active Smokers
  • Current or previous malignancy up to 5 years prior to screening
  • History of allergy to BMS-986278 or related compounds

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
403 participants (actual)

Study arms

  • Experimental
    IPF Dose 1 + Post Treatment Follow-up or OTE

    IPF (Idiopathic Pulmonary Fibrosis) OTE (Optional Treatment Extension)

    Drug: BMS-986278

  • Experimental
    IPF Dose 2 + Post Treatment Follow-up or OTE

    Drug: BMS-986278

  • Placebo comparator
    IPF Placebo + Post Treatment Follow-up or OTE

    Other: BMS-986278 Placebo

  • Experimental
    PF-ILD Dose 1 + Post Treatment Follow-up or OTE

    PF-ILD (Progressive Fibrotic Interstitial Lung Disease)

    Drug: BMS-986278

  • Experimental
    PF-ILD Dose 2 + Post Treatment Follow-up or OTE

    Drug: BMS-986278

  • Placebo comparator
    PF-ILD Placebo + Post Treatment Follow-up or OTE

    Other: BMS-986278 Placebo

Interventions

  • OtherBMS-986278 Placebo

    Specified Dose on Specified Days

  • Specified Dose on Specified Days

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in IPF Participants

    Percent predicted forced vital capacity (ppFVC) is the percentage of predicted value per participant of forced vital capacity (FVC). FVC is defined as the maximum capacity of air that a participant can exhale after a maximum inspiration as measured by the volume of air exhaled in a spirometer. The data is reported as percent change from baseline in ppFVC. Percent change from baseline is a calculation that expresses the change in a value compared to its initial starting point (baseline) as a percentage, showing how much a value has increased or decreased relative to its original level; it's calculated by subtracting the baseline value from the new value, dividing by the baseline value, and then multiplying by 100%. The percent change in this endpoint was calculated from ppFVC values taken at baseline, which is defined as the measurement of ppFVC taken at first dose, and ppFVC values taken at Week 26. This endpoint reports data for the IPF cohort only as pre-specified in the protocol.

    Time frame: From baseline (first dose) up to week 26

Secondary outcomes

  1. The Number of Participants Experiencing Adverse Events (AEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

    Time frame: From first dose up to 30 days after last dose during the main study treatment phase

  2. The Number of Participants Experiencing Serious Adverse Events (SAEs)

    A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.

    Time frame: From first dose up to 30 days after last dose during the main study treatment phase

  3. The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation

    The number of participants who discontinued study treatment due to adverse events (AEs)

    Time frame: From first dose up to 30 days after last dose during the main study treatment phase

  4. The Number of Participants Who Died Due to Adverse Events (AEs)

    The number of participants who died while receiving study treatment due to an adverse event

    Time frame: From first dose up to 30 days after last dose during the main study treatment phase

  5. Maximum Concentration (Cmax)

    Cmax is defined as the maximum concentration of the analyte recorded in the participants. Cmax of BMS-986278 and BMT-327319 was derived from plasma concentration versus time data.

    Time frame: On Day 1 and Week 4 (Day 29)

  6. Time to Maximum Concentration (Tmax)

    Tmax is defined as the amount of time until the maximum concentration of the analyte is recorded in the participants

    Time frame: On Day 1 and Week 4 (Day 29)

  7. Area Under Curve (AUC0-8)

    Area under the plasma concentration-time curve (AUC) from the timepoint of 0 hours to 24 hours post dose as measured on Day 1 and Week 4.

    Time frame: On Day 1 and Week 4 (Day 29)

  8. Concentration Trough (Ctrough)

    Ctrough is defined as the lowerst concentration of drug in the blood immediately before the next dose is administered

    Time frame: On Week 4 (Day 29) and Week 12 (Day 85)

  9. The Number of Participants Experiencing Electrocardiogram (ECG) Abnormalities

    A frequency summary of investigator clinical interpretation of ECG abnormal findings is listed.

    Time frame: At Week 26

  10. Change From Baseline in Vital Sign Measurements

    The change from baseline in select vital sign measurements. Baseline is defined as first dose.

    Time frame: At baseline and Week 26

  11. Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in PF-ILD Participants

    Percent predicted forced vital capacity (ppFVC) is the percentage of predicted value per participant of forced vital capacity (FVC). FVC is defined as the maximum capacity of air that a participant can exhale after a maximum inspiration as measured by the volume of air exhaled in a spirometer. The data is reported as percent change from baseline in ppFVC. Percent change from baseline is a calculation that expresses the change in a value compared to its initial starting point (baseline) as a percentage, showing how much a value has increased or decreased relative to its original level; it's calculated by subtracting the baseline value from the new value, dividing by the baseline value, and then multiplying by 100%. The percent change in this endpoint was calculated from ppFVC values taken at baseline, which is defined as the measurement of ppFVC taken at first dose, and ppFVC values taken at Week 26. This endpoint reports data for PF-ILD cohort only as pre-specified in the protocol.

    Time frame: At baseline and Week 26

  12. The Number of Participants With ≥ 10% Absolute Decline in ppFVC (%)

    The number of participants with ≥ 10% absolute decline in percent predicted forced vital capacity (ppFVC) at pre-specified timepoints. ppFVC is the maximum capacity of air that a participant can exhale after a maximum inspiration. It measures the volume of air exhaled in a spirometer, after a maximal inspiration. It is reported as the percentage of the predicted value for the participant. The number of participants represented signify the number of participants with applicable data during the specific visit at the specific timepoint.

    Time frame: At Weeks 4, 8, 12, 16, 20, and 26

  13. The Number of Participants With 0% Change in ppFVC (%)

    The number of participants with 0% change in percent predicted forced vital capacity (ppFVC) at pre-specified timepoints. ppFVC is the maximum capacity of air that a participant can exhale after a maximum inspiration. It measures the volume of air exhaled in a spirometer, after a maximal inspiration. It is reported as the percentage of the predicted value for the participant.

    Time frame: Weeks 4, 8, 12, 16, 20, and 26

  14. Time to First Occurrence ≥ 10% Absolute Decline in ppFVC (%)

    The amount of time in weeks to the participant's first occurrence ≥ 10% absolute decline in Percent Predicted Forced Vital Capacity (ppFVC). A participant's time is censored at the last observed time prior to discontinuation if a participant discontinues study without event, or at week 26 if a participant does not experience the event until the end of week 26. Kaplan-Meier product limit method will be employed to estimate the survival curves. ppFVC is the maximum capacity of air that a participant can exhale after a maximum inspiration. It measures the volume of air exhaled in a spirometer, after a maximal inspiration. It is reported as the percentage of the predicted value for the participant.

    Time frame: From first dose up to the first occurrence of ≥ 10% absolute decline in ppFVC

  15. Absolute Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC)

    The absolute change in ppFVC (%) is measured from baseline up to the pre-specified timepoints of Weeks 4, 8, 12, 16, 20, and 26. ppFVC is the maximum capacity of air that a participant can exhale after a maximum inspiration. It measures the volume of air (mL) exhaled in a spirometer, after a maximal inspiration. It is reported as the percentage of the predicted value for the participant.

    Time frame: From baseline up to Weeks 4, 8, 12, 16, 20, and 26

  16. Absolute Change From Baseline in Forced Vital Capacity (FVC)

    Forced vital capacity (FVC) is defined as the amount of air that can be forcibly exhaled from your lungs after taking the deepest breath possible. The absolute change in FVC (mL) is measured from baseline up to Weeks 4, 8, 12, 16, 20, and 26.

    Time frame: From baseline up to Weeks 4, 8, 12, 16, 20, and 26

  17. Absolute Change From Baseline in Single Breath Diffusing Capacity of Carbon Monoxide (DLCO SB)

    The absolute change in single breath diffusing capacity of carbon monoxide (DLCO SB) (mL/min/mmHg) (corrected for hemoglobin) from baseline to Week 26. DLCO is defined as a measurement of the extent to which oxygen passes from the alveoli into the blood. Baseline is defined as first dose.

    Time frame: From baseline up to Week 26

  18. Absolute Change From Baseline in Percent Predicted Single Breath Diffusing Capacity of Carbon Monoxide (ppDLCO SB)

    The absolute change in percent predicted single breath diffusing capacity of carbon monoxide (DLCO SB) (mL/min/mmHg) (corrected for hemoglobin) from baseline to Week 26. DLCO is defined as a measurement of the extent to which oxygen passes from the alveoli into the blood. Baseline is defined as first dose.

    Time frame: From baseline up to Week 26

  19. Absolute Change From Baseline in Walking Endurance/Distance

    The absolute change in walking endurance/distance as determined by the 6-minute walk test (6MWT) from baseline to Week 26. The 6-Minute Walk Test (6MWT) is a submaximal exercise test used to assess aerobic capacity and endurance. Baseline is defined as first dose.

    Time frame: From baseline up to Week 26

  20. Time to First Acute Exacerbation

    Time to first acute exacerbations of lung fibrosis was measured from the day of first dose up to the day of first acute exacerbation. Participants who discontinued the study treatment prior to the end of the main study without experiencing the event were excluded from the analysis. A participant's time was censored at the last observed time prior to discontinuation if a participant discontinued study without event, or at week 26 if a participant did not experience the event until the end of week 26. Acute exacerbations were defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality, as follows: 1. Acute worsening or development of dyspnea (\< 1 month duration) 2. Imaging with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with usual interstitial pneumonia 3. Respiratory deterioration not fully explained by cardiac failure or fluid overload

    Time frame: From the first dose up to the day of the first acute exacerbation or Week 26, whichever comes first

  21. The Number of Participants Experiencing Acute Exacerbation

    The number of participants experiencing acute exacerbations of lung fibrosis. Acute exacerbations were defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality, as follows: 1. Acute worsening or development of dyspnea (\< 1 month duration) 2. Imaging with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with usual interstitial pneumonia 3. Respiratory deterioration not fully explained by cardiac failure or fluid overload

    Time frame: From the first dose up to the day of the first acute exacerbation or Week 26, whichever comes first

07

Results

Posted Feb 24, 2025

Participant flow

Pre-Treatment
Participant flow — Pre-Treatment
MilestoneIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278IPF Cohort - BMS-986278 10mgPF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278PF-ILD Cohort - 10mg BMS-986278
Started93929304142420
Completed92919304140420
Not completed11000200
Withdrew: Not reported11000200
Treatment up to Week 26
Participant flow — Treatment up to Week 26
MilestoneIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278IPF Cohort - BMS-986278 10mgPF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278PF-ILD Cohort - 10mg BMS-986278
Started92919304140420
Completed82828403337400
Not completed109908320
Withdrew: Withdrawal by participant21100110
Withdrew: Other reasons20001100
Withdrew: Participant no longer meets study criteria01201010
Withdrew: Adverse event65506100
Withdrew: Adverse event unrelated to study drug02100000
OTE - 26 Weeks
Participant flow — OTE - 26 Weeks
MilestoneIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278IPF Cohort - BMS-986278 10mgPF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278PF-ILD Cohort - 10mg BMS-986278
Started010010211041464
Pbo bms-986278 30 mg0330001300
Pbo bms-986278 60 mg0030000140
Completed096898039424
Not completed041330240
Withdrew: Withdrawal by participant00400010
Withdrew: Death01000010
Withdrew: Adverse event02830120
Withdrew: Adverse event unrelated to study drug01100100

Outcome measures

PrimaryChange From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in IPF Participants

Percent predicted forced vital capacity (ppFVC) is the percentage of predicted value per participant of forced vital capacity (FVC). FVC is defined as the maximum capacity of air that a participant can exhale after a maximum inspiration as measured by the volume of air exhaled in a spirometer. The data is reported as percent change from baseline in ppFVC. Percent change from baseline is a calculation that expresses the change in a value compared to its initial starting point (baseline) as a percentage, showing how much a value has increased or decreased relative to its original level; it's calculated by subtracting the baseline value from the new value, dividing by the baseline value, and then multiplying by 100%. The percent change in this endpoint was calculated from ppFVC values taken at baseline, which is defined as the measurement of ppFVC taken at first dose, and ppFVC values taken at Week 26. This endpoint reports data for the IPF cohort only as pre-specified in the protocol.

Time frame:
From baseline (first dose) up to week 26
Reported as:
Mean · Percent change from baseline in ppFVC
Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in IPF Participants
Percent change from baseline in ppFVCIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in IPF Participants-2.807 ± 0.7286-3.068 ± 0.7335-1.120 ± 0.6691———
SecondaryThe Number of Participants Experiencing Adverse Events (AEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

Time frame:
From first dose up to 30 days after last dose during the main study treatment phase
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Adverse Events (AEs)
ParticipantsIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
The Number of Participants Experiencing Adverse Events (AEs)746969323328
SecondaryThe Number of Participants Experiencing Serious Adverse Events (SAEs)

A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.

Time frame:
From first dose up to 30 days after last dose during the main study treatment phase
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Serious Adverse Events (SAEs)
ParticipantsIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
The Number of Participants Experiencing Serious Adverse Events (SAEs)1610101346
SecondaryThe Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation

The number of participants who discontinued study treatment due to adverse events (AEs)

Time frame:
From first dose up to 30 days after last dose during the main study treatment phase
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
ParticipantsIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation996710
SecondaryThe Number of Participants Who Died Due to Adverse Events (AEs)

The number of participants who died while receiving study treatment due to an adverse event

Time frame:
From first dose up to 30 days after last dose during the main study treatment phase
Reported as:
Count of participants · Participants
The Number of Participants Who Died Due to Adverse Events (AEs)
ParticipantsIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
The Number of Participants Who Died Due to Adverse Events (AEs)234300
SecondaryMaximum Concentration (Cmax)

Cmax is defined as the maximum concentration of the analyte recorded in the participants. Cmax of BMS-986278 and BMT-327319 was derived from plasma concentration versus time data.

Time frame:
On Day 1 and Week 4 (Day 29)
Reported as:
Geometric mean · ng/mL
Maximum Concentration (Cmax)
ng/mLIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
Day 1; Analyte: BMS-986278—465.0 ± 36.231089.8 ± 42.06—715.4 ± 2.871112.3 ± 77.45
Day 1; Analyte: BMT-323719—114.66 ± 32.147167.35 ± 39.538—94.8 ± 10.39189.6 ± 86.07
Day 29; Analyte: BMS-986278—641.0 ± 27.681301.3 ± 20.80—691.9 ± 2.041247.80 ± 29.84
Day 29; Analyte: BMT-323719—169.30 ± 28.104275.82 ± 34.554—161.9 ± 30.60433.5 ± 58.73
SecondaryTime to Maximum Concentration (Tmax)

Tmax is defined as the amount of time until the maximum concentration of the analyte is recorded in the participants

Time frame:
On Day 1 and Week 4 (Day 29)
Reported as:
Median · Hours
Time to Maximum Concentration (Tmax)
HoursIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
Day 1; Analyte: BMS-986278—2.0170 (1.567 to 4.100)1.6670 (1.283 to 5.917)—1.55 (1.50 to 1.60)2.01 (1.83 to 2.18)
Day 1; Analyte: BMT-323719—4.0670 (1.867 to 7.900)4.0330 (1.900 to 8.000)—7.96 (7.92 to 8.00)4.10 (3.98 to 4.22)
Day 29; Analyte: BMS-986278—1.9080 (1.450 to 4.117)1.6750 (1.317 to 4.000)—2.68 (1.533 to 3.82)4.06 (3.98 to 4.13)
Day 29; Analyte: BMT-323719—4.0670 (2.083 to 6.000)2.0085 (1.417 to 7.850)—5.79 (4.10 to 7.48)3.74 (1.48 to 6.00)
SecondaryArea Under Curve (AUC0-8)

Area under the plasma concentration-time curve (AUC) from the timepoint of 0 hours to 24 hours post dose as measured on Day 1 and Week 4.

Time frame:
On Day 1 and Week 4 (Day 29)
Reported as:
Geometric mean · h*ng/mL
Area Under Curve (AUC0-8)
h*ng/mLIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
Day 1; Analyte: BMS-986278—1990.4530 ± 20.781854430.5891 ± 31.16188—3358 ± 8.74347 ± 61.3
Day 1; Analyte: BMT-323719—686.2045 ± 32.95587913.4300 ± 50.72949—532 ± NA2081 ± NA
Day 29; Analyte: BMS-986278—2853.9081 ± 21.721085433.1662 ± 25.62819—3591 ± NA8107 ± NA
Day 29; Analyte: BMT-323719—1179.6486 ± 31.279871784.7369 ± 30.32795——2839 ± 45.8
SecondaryConcentration Trough (Ctrough)

Ctrough is defined as the lowerst concentration of drug in the blood immediately before the next dose is administered

Time frame:
On Week 4 (Day 29) and Week 12 (Day 85)
Reported as:
Median · ng/mL
Concentration Trough (Ctrough)
ng/mLIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
Day 29-BMS-986278—92.1 (13.5 to 433)217 (32.4 to 1540)—116.0000 (26.300 to 392.000)286.0000 (49.600 to 2659.000)
Day 85-BMS-986278—84.2 (16.7 to 389)199 (5.37 to 726)—88.7000 (20.100 to 380.000)196.0000 (68.000 to 1773.000)
Day 29-BMT-323719—60.3 (12.9 to 207)141 (52.4 to 384)—75.5000 (0.200 to 121.000)177.5000 (0.200 to 693.000)
Day 85-BMT-323719—64.2 (0.200 to 174)132 (0.200 to 371)—67.4500 (11.000 to 186.000)156.0000 (0.200 to 326.000)
SecondaryThe Number of Participants Experiencing Electrocardiogram (ECG) Abnormalities

A frequency summary of investigator clinical interpretation of ECG abnormal findings is listed.

Time frame:
At Week 26
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Electrocardiogram (ECG) Abnormalities
ParticipantsIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
The Number of Participants Experiencing Electrocardiogram (ECG) Abnormalities2718315912
SecondaryChange From Baseline in Vital Sign Measurements

The change from baseline in select vital sign measurements. Baseline is defined as first dose.

Time frame:
At baseline and Week 26
Reported as:
Median · Change from baseline in mmHg
Change From Baseline in Vital Sign Measurements
Change from baseline in mmHgIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
Sitting Diastolic Blood Pressure - 0 Hours Pre-Dose0.0 (-20 to 19)0.0 (-21 to 20)1.0 (-16 to 24)3.0 (-9 to 13)1.0 (-18 to 17)-1.0 (-27 to 15)
Standing Diastolic Blood Pressure - 0 Hours Pre-Dose-2.0 (-18 to 15)0.0 (-28 to 22)1.0 (-24 to 30)1.5 (-15 to 26)-0.5 (-14 to 20)0.0 (-18 to 16)
Supine Diastolic Blood Pressure - 0 Hours Pre-Dose-1.0 (-12 to 18)1.0 (-25 to 17)1.0 (-23 to 19)2.5 (-13 to 15)0.0 (-8 to 17)0.0 (-14 to 14)
Sitting Systolic Blood Pressure - 0 Hours Pre-Dose-1.0 (-29 to 37)1.0 (-23 to 30)3.0 (-22 to 34)0.0 (-35 to 17)1.0 (-22 to 37)-1.0 (-49 to 34)
Standing Systolic Blood Pressure - 0 Hours Pre-Dose-3.0 (-27 to 28)-1.5 (-35 to 31)3.0 (-28 to 36)0.5 (-38 to 33)0.5 (-23 to 28)0.0 (-34 to 26)
Supine Systolic Blood Pressure - 0 Hours Pre-Dose0.0 (-24 to 34)0.0 (-25 to 43)3.0 (-24 to 24)2.5 (-29 to 25)2.0 (-20 to 49)-3.0 (-30 to 23)
SecondaryChange From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in PF-ILD Participants

Percent predicted forced vital capacity (ppFVC) is the percentage of predicted value per participant of forced vital capacity (FVC). FVC is defined as the maximum capacity of air that a participant can exhale after a maximum inspiration as measured by the volume of air exhaled in a spirometer. The data is reported as percent change from baseline in ppFVC. Percent change from baseline is a calculation that expresses the change in a value compared to its initial starting point (baseline) as a percentage, showing how much a value has increased or decreased relative to its original level; it's calculated by subtracting the baseline value from the new value, dividing by the baseline value, and then multiplying by 100%. The percent change in this endpoint was calculated from ppFVC values taken at baseline, which is defined as the measurement of ppFVC taken at first dose, and ppFVC values taken at Week 26. This endpoint reports data for PF-ILD cohort only as pre-specified in the protocol.

Time frame:
At baseline and Week 26
Reported as:
Mean · Percent change from baseline
Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in PF-ILD Participants
Percent change from baselineIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in PF-ILD Participants———-2.681 ± 1.47302.717 ± 0.9054-1.203 ± 0.8808
SecondaryThe Number of Participants With ≥ 10% Absolute Decline in ppFVC (%)

The number of participants with ≥ 10% absolute decline in percent predicted forced vital capacity (ppFVC) at pre-specified timepoints. ppFVC is the maximum capacity of air that a participant can exhale after a maximum inspiration. It measures the volume of air exhaled in a spirometer, after a maximal inspiration. It is reported as the percentage of the predicted value for the participant. The number of participants represented signify the number of participants with applicable data during the specific visit at the specific timepoint.

Time frame:
At Weeks 4, 8, 12, 16, 20, and 26
Reported as:
Count of participants · Participants
The Number of Participants With ≥ 10% Absolute Decline in ppFVC (%)
ParticipantsIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
Week 4302000
Week 8443200
Week 12413100
Week 16322200
Week 201011210
Week 26774331
SecondaryThe Number of Participants With 0% Change in ppFVC (%)

The number of participants with 0% change in percent predicted forced vital capacity (ppFVC) at pre-specified timepoints. ppFVC is the maximum capacity of air that a participant can exhale after a maximum inspiration. It measures the volume of air exhaled in a spirometer, after a maximal inspiration. It is reported as the percentage of the predicted value for the participant.

Time frame:
Weeks 4, 8, 12, 16, 20, and 26
Reported as:
Count of participants · Participants
The Number of Participants With 0% Change in ppFVC (%)
ParticipantsIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
Week 4484133141213
Week 8474369151312
Week 12464339171313
Week 16514539151118
Week 20514033181518
Week 26534234172219
SecondaryTime to First Occurrence ≥ 10% Absolute Decline in ppFVC (%)

The amount of time in weeks to the participant's first occurrence ≥ 10% absolute decline in Percent Predicted Forced Vital Capacity (ppFVC). A participant's time is censored at the last observed time prior to discontinuation if a participant discontinues study without event, or at week 26 if a participant does not experience the event until the end of week 26. Kaplan-Meier product limit method will be employed to estimate the survival curves. ppFVC is the maximum capacity of air that a participant can exhale after a maximum inspiration. It measures the volume of air exhaled in a spirometer, after a maximal inspiration. It is reported as the percentage of the predicted value for the participant.

Time frame:
From first dose up to the first occurrence of ≥ 10% absolute decline in ppFVC
Reported as:
Median · Weeks
Time to First Occurrence ≥ 10% Absolute Decline in ppFVC (%)
WeeksIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
Time to First Occurrence ≥ 10% Absolute Decline in ppFVC (%)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (26.3 to NA)NA (NA to NA)
SecondaryAbsolute Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC)

The absolute change in ppFVC (%) is measured from baseline up to the pre-specified timepoints of Weeks 4, 8, 12, 16, 20, and 26. ppFVC is the maximum capacity of air that a participant can exhale after a maximum inspiration. It measures the volume of air (mL) exhaled in a spirometer, after a maximal inspiration. It is reported as the percentage of the predicted value for the participant.

Time frame:
From baseline up to Weeks 4, 8, 12, 16, 20, and 26
Reported as:
Mean · Percentage of predicted value
Absolute Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC)
Percentage of predicted valueIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
Absolute change from Baseline to Week 4-1.491 ± 4.3773-0.482 ± 4.24990.023 ± 5.40071.119 ± 6.01230.327 ± 3.18620.217 ± 3.5946
Absolute change from Baseline to Week 8-1.783 ± 4.5234-1.046 ± 4.8192-1.079 ± 5.1294-0.334 ± 7.63260.966 ± 3.26310.475 ± 3.2802
Absolute change from Baseline to Week 12-1.974 ± 5.0324-0.589 ± 4.8575-1.109 ± 5.9152-2.012 ± 5.54360.114 ± 4.24900.196 ± 3.7168
Absolute change from Baseline to Week 16-2.422 ± 5.0040-1.042 ± 5.1644-1.220 ± 4.3475-1.180 ± 7.6897-0.197 ± 4.5490-0.394 ± 4.3439
Absolute change from Baseline to Week 20-2.625 ± 4.8978-1.717 ± 3.9049-0.387 ± 4.2802-2.650 ± 4.2813-0.382 ± 4.6328-0.272 ± 6.0198
Absolute change from Baseline to Week 26-2.807 ± 6.0959-3.068 ± 5.6339-1.120 ± 5.4768-2.681 ± 6.9089-2.717 ± 4.8758-1.203 ± 4.9043
SecondaryAbsolute Change From Baseline in Forced Vital Capacity (FVC)

Forced vital capacity (FVC) is defined as the amount of air that can be forcibly exhaled from your lungs after taking the deepest breath possible. The absolute change in FVC (mL) is measured from baseline up to Weeks 4, 8, 12, 16, 20, and 26.

Time frame:
From baseline up to Weeks 4, 8, 12, 16, 20, and 26
Reported as:
Mean · mL
Absolute Change From Baseline in Forced Vital Capacity (FVC)
mLIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
Absolute change from Baseline to Week 4-54.7 ± 153.50-21.2 ± 142.254.3 ± 181.7539.1 ± 152.576.0 ± 107.11-0.30 ± 113.07
Absolute change from Baseline to Week 8-62.7 ± 157.81-38.2 ± 173.96-36.1 ± 165.74-8.8 ± 180.1024.7 ± 92.8711.2 ± 106.11
Absolute change from Baseline to Week 12-75.5 ± 184.02-27.2 ± 173.23-35.4 ± 176.48-61.6 ± 177.42-1.5 ± 129.640.9 ± 128.40
Absolute change from Baseline to Week 16-88.2 ± 183.44-41.0 ± 184.89-45.8 ± 152.79-44.3 ± 222.44-22.8 ± 146.75-12.1 ± 140.79
Absolute change from Baseline to Week 20-95.6 ± 181.41-70.0 ± 142.70-21.1 ± 154.05-84.6 ± 134.01-15.2 ± 168.21-3.9 ± 222.29
Absolute change from Baseline to Week 26-106.4 ± 214.94-117.3 ± 207.60-48.8 ± 184.97-99.1 ± 212.04-100.0 ± 166.30-37.7 ± 179.38
SecondaryAbsolute Change From Baseline in Single Breath Diffusing Capacity of Carbon Monoxide (DLCO SB)

The absolute change in single breath diffusing capacity of carbon monoxide (DLCO SB) (mL/min/mmHg) (corrected for hemoglobin) from baseline to Week 26. DLCO is defined as a measurement of the extent to which oxygen passes from the alveoli into the blood. Baseline is defined as first dose.

Time frame:
From baseline up to Week 26
Reported as:
Median · mL/min/mmHg
Absolute Change From Baseline in Single Breath Diffusing Capacity of Carbon Monoxide (DLCO SB)
mL/min/mmHgIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
Absolute Change From Baseline in Single Breath Diffusing Capacity of Carbon Monoxide (DLCO SB)-0.4664 (-17.023 to 5.725)-0.3418 (-14.024 to 3.190)-0.4518 (-5.449 to 3.888)-0.2352 (-15.031 to 9.564)-0.3269 (-8.902 to 2.086)-0.1829 (-12.766 to 7.063)
SecondaryAbsolute Change From Baseline in Percent Predicted Single Breath Diffusing Capacity of Carbon Monoxide (ppDLCO SB)

The absolute change in percent predicted single breath diffusing capacity of carbon monoxide (DLCO SB) (mL/min/mmHg) (corrected for hemoglobin) from baseline to Week 26. DLCO is defined as a measurement of the extent to which oxygen passes from the alveoli into the blood. Baseline is defined as first dose.

Time frame:
From baseline up to Week 26
Reported as:
Median · Percentage of predicted value
Absolute Change From Baseline in Percent Predicted Single Breath Diffusing Capacity of Carbon Monoxide (ppDLCO SB)
Percentage of predicted valueIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
Absolute Change From Baseline in Percent Predicted Single Breath Diffusing Capacity of Carbon Monoxide (ppDLCO SB)-1.4634 (-38.133 to 64.451)-0.3470 (-26.548 to 51.300)-3.2455 (-48.939 to 35.463)-1.000 (-22.176 to 11.587)-1.4683 (-62.971 to 13.767)-1.4609 (-13.016 to 20.997)
SecondaryAbsolute Change From Baseline in Walking Endurance/Distance

The absolute change in walking endurance/distance as determined by the 6-minute walk test (6MWT) from baseline to Week 26. The 6-Minute Walk Test (6MWT) is a submaximal exercise test used to assess aerobic capacity and endurance. Baseline is defined as first dose.

Time frame:
From baseline up to Week 26
Reported as:
Median · Meters
Absolute Change From Baseline in Walking Endurance/Distance
MetersIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
Absolute Change From Baseline in Walking Endurance/Distance0.0 (-495 to 119)3.0 (-260 to 138)6.0 (-370 to 92)11.0000 (-315.833 to 175.000)0.0000 (-220.000 to 188.400)-14.0000 (-173.000 to 242.857)
SecondaryTime to First Acute Exacerbation

Time to first acute exacerbations of lung fibrosis was measured from the day of first dose up to the day of first acute exacerbation. Participants who discontinued the study treatment prior to the end of the main study without experiencing the event were excluded from the analysis. A participant's time was censored at the last observed time prior to discontinuation if a participant discontinued study without event, or at week 26 if a participant did not experience the event until the end of week 26. Acute exacerbations were defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality, as follows: 1. Acute worsening or development of dyspnea (\< 1 month duration) 2. Imaging with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with usual interstitial pneumonia 3. Respiratory deterioration not fully explained by cardiac failure or fluid overload

Time frame:
From the first dose up to the day of the first acute exacerbation or Week 26, whichever comes first
Reported as:
Median · Weeks
Time to First Acute Exacerbation
WeeksIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
Time to First Acute ExacerbationNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)—NA (NA to NA)
SecondaryThe Number of Participants Experiencing Acute Exacerbation

The number of participants experiencing acute exacerbations of lung fibrosis. Acute exacerbations were defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality, as follows: 1. Acute worsening or development of dyspnea (\< 1 month duration) 2. Imaging with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with usual interstitial pneumonia 3. Respiratory deterioration not fully explained by cardiac failure or fluid overload

Time frame:
From the first dose up to the day of the first acute exacerbation or Week 26, whichever comes first
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Acute Exacerbation
ParticipantsIPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278
The Number of Participants Experiencing Acute Exacerbation231301

Adverse events

Collected over Participants were assessed for all-cause mortality from their randomization to study completion, (up to approximately 58 weeks). SAEs and Other AEs were assessed from first dose to 30 days following last dose (up to approximately 58 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IPF Cohort - Main Study - Placebo4/92 (4.3%)16/92 (17.4%)57/92 (62%)
IPF Cohort - Main Study - 30 mg BMS-9862784/91 (4.4%)10/91 (11%)54/91 (59.3%)
IPF Cohort - Main Study - BMS-986278 60mg5/93 (5.4%)10/93 (10.8%)51/93 (54.8%)
IPF Cohort - BMS-986278 10mg3/11 (27.3%)4/11 (36.4%)8/11 (72.7%)
IPF Cohort - OTE Phase - PBO BMS-986278 30 mg4/100 (4%)19/100 (19%)40/100 (40%)
IPF Cohort - OTE Phase - PBO BMS-986278 60mg6/102 (5.9%)23/102 (22.5%)43/102 (42.2%)
PF-ILD Cohort - Main Study - Placebo4/41 (9.8%)13/41 (31.7%)19/41 (46.3%)
PF-ILD Cohort - Main Study - BMS-986278 30mg0/40 (0%)4/40 (10%)23/40 (57.5%)
PF-ILD Cohort - Main Study - BMS-986278 60mg0/42 (0%)6/42 (14.3%)24/42 (57.1%)
PF-ILD Cohort - OTE Phase - BMS-986278 10mg0/4 (0%)0/4 (0%)4/4 (100%)
PF-ILD Cohort - OTE Phase - PBO BMS-986278 30mg1/41 (2.4%)8/41 (19.5%)18/41 (43.9%)
PF-ILD Cohort - OTE Phase - PBO BMS-986278 60mg3/46 (6.5%)7/46 (15.2%)23/46 (50%)
Most frequent serious events
Showing 10 of 86
Most frequent serious events
EventIPF Cohort - Main Study - PlaceboIPF Cohort - Main Study - 30 mg BMS-986278IPF Cohort - Main Study - BMS-986278 60mgIPF Cohort - BMS-986278 10mgIPF Cohort - OTE Phase - PBO BMS-986278 30 mgIPF Cohort - OTE Phase - PBO BMS-986278 60mgPF-ILD Cohort - Main Study - PlaceboPF-ILD Cohort - Main Study - BMS-986278 30mgPF-ILD Cohort - Main Study - BMS-986278 60mgPF-ILD Cohort - OTE Phase - BMS-986278 10mgPF-ILD Cohort - OTE Phase - PBO BMS-986278 30mgPF-ILD Cohort - OTE Phase - PBO BMS-986278 60mg
Respiratory tract infectionInfections and infestations0/920/910/931/110/1001/1020/410/400/420/40/410/46
Forced vital capacity decreasedInvestigations0/920/910/931/110/1000/1020/410/400/420/40/410/46
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/920/910/931/111/1000/1020/410/400/420/40/411/46
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders3/924/910/931/118/1007/1021/410/400/420/41/410/46
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders1/921/910/930/110/1000/1022/410/401/420/41/410/46
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/920/910/930/110/1003/1020/410/400/420/40/410/46
COVID-19Infections and infestations0/920/910/930/111/1001/1020/411/400/420/41/410/46
Pneumocystis jirovecii pneumoniaInfections and infestations0/920/910/930/110/1000/1020/411/400/420/40/410/46
Pneumonia legionellaInfections and infestations0/920/910/930/110/1000/1020/411/400/420/40/410/46
Femur fractureInjury, poisoning and procedural complications0/920/910/930/110/1000/1020/411/400/420/40/410/46
Most frequent other events
Showing 10 of 39
Most frequent other events
EventIPF Cohort - Main Study - PlaceboIPF Cohort - Main Study - 30 mg BMS-986278IPF Cohort - Main Study - BMS-986278 60mgIPF Cohort - BMS-986278 10mgIPF Cohort - OTE Phase - PBO BMS-986278 30 mgIPF Cohort - OTE Phase - PBO BMS-986278 60mgPF-ILD Cohort - Main Study - PlaceboPF-ILD Cohort - Main Study - BMS-986278 30mgPF-ILD Cohort - Main Study - BMS-986278 60mgPF-ILD Cohort - OTE Phase - BMS-986278 10mgPF-ILD Cohort - OTE Phase - PBO BMS-986278 30mgPF-ILD Cohort - OTE Phase - PBO BMS-986278 60mg
Dental cariesGastrointestinal disorders0/920/911/931/110/1000/1020/410/400/421/40/411/46
FatigueGeneral disorders4/925/911/930/112/1004/1021/410/403/421/41/411/46
BronchitisInfections and infestations1/924/911/931/114/1005/1022/411/400/421/42/413/46
COVID-19Infections and infestations7/923/919/931/1112/1008/1022/415/406/421/47/416/46
InfluenzaInfections and infestations0/920/911/930/110/1000/1020/411/400/421/40/411/46
Upper respiratory tract infectionInfections and infestations1/923/911/930/111/1003/1021/410/403/421/41/411/46
Blood bilirubin increasedInvestigations0/920/910/930/110/1000/1020/411/400/421/41/410/46
Decreased appetiteMetabolism and nutrition disorders1/921/914/930/111/1000/1020/411/400/421/40/410/46
ArthralgiaMusculoskeletal and connective tissue disorders5/924/914/930/113/1000/1021/410/402/421/41/412/46
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/920/910/930/111/1000/1020/410/400/421/40/410/46

Baseline characteristics

The baseline characteristics are reported for the safety population which is all treated participants.

Age, Continuous
Age, Continuous(Years)IPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278Total
Mean69.0 ± 6.7069.5 ± 7.3168.8 ± 7.8568.8 ± 8.0671.4 ± 7.9267.9 ± 8.4169.5 ± 8.22
Sex: Female, Male
Sex: Female, Male(Participants)IPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278Total
Female161424211720112
Male767769202322287
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278Total
Hispanic or Latino21181976980
Not Hispanic or Latino393637192122174
Unknown or Not Reported323737151311145
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IPF Cohort: PlaceboIPF Cohort: 30 mg BMS-986278IPF Cohort: 60 mg BMS-986278PF-ILD Cohort: PlaceboPF-ILD Cohort: 30 mg BMS-986278PF-ILD Cohort: 60 mg BMS-986278Total
American Indian or Alaska Native0010001
Asian252527896100
Native Hawaiian or Other Pacific Islander0000000
Black or African American1000203
White656464312732283
More than one race0000000
Unknown or Not Reported12122412
08

Study locations

119 sites
  • Local Institution - 0032
    Birmingham, Alabama 35294, United States
  • Local Institution
    Phoenix, Arizona 85006, United States
  • Local Institution - 0028
    Los Angeles, California 90024, United States
  • Local Institution - 0043
    Stanford, California 94305-528, United States
  • University of Colorado Anschutz Medical Campus-Department of Medicine
    Aurora, Colorado 80045, United States
  • Local Institution - 0006
    Denver, Colorado 80206, United States
  • Local Institution - 0171
    New Haven, Connecticut 06520, United States
  • Local Institution - 0035
    Gainesville, Florida 32610, United States
  • Local Institution - 0166
    Orlando, Florida 32803, United States
  • Local Institution - 0078
    Atlanta, Georgia 30309, United States
  • Local Institution - 0031
    Kansas City, Kansas 66160, United States
  • Local Institution - 0154
    Baltimore, Maryland 21224, United States
  • Local Institution - 0003
    Boston, Massachusetts 02135, United States
  • Local Institution - 0030
    Chesterfield, Missouri 63017, United States
  • Local Institution - 0036
    St Louis, Missouri 63110, United States
  • Local Institution - 0029
    Cincinnati, Ohio 45267, United States
  • Local Institution - 0164
    Columbus, Ohio 43221, United States
  • Local Institution
    Hershey, Pennsylvania 17033, United States
  • Local Institution
    Nashville, Tennessee 37232, United States
  • Local Institution - 0096
    Charlottesville, Virginia 22908, United States
  • Local Institution
    Falls Church, Virginia 22042, United States
  • Local Institution - 0049
    Buenos Aires, Distrito Federal 1425, Argentina
  • Local Institution - 0103
    Rosario, Santa Fe Province S2000DTC, Argentina
  • Local Institution - 0097
    San Miguel de Tucumán, Tucumán Province T4000IAR, Argentina
  • Local Institution - 0115
    Buenos Aires, 1056, Argentina
  • Local Institution - 0048
    Buenos Aires, 1638, Argentina
  • Local Institution - 0122
    Mendoza, 5500, Argentina
  • Local Institution - 0045
    Camperdown, New South Wales 2050, Australia
  • Local Institution - 0025
    Westmead, New South Wales 2145, Australia
  • Local Institution - 0026
    Brisbane, Queensland 4032, Australia
  • Local Institution - 0046
    Greenslopes, Queensland 4120, Australia
  • Local Institution - 0022
    Adelaide, South Australia 5000, Australia
  • Local Institution - 0023
    Heidelberg, Victoria 3084, Australia
  • Local Institution - 0021
    Murdoch, Western Australia 6150, Australia
  • Local Institution - 0044
    Nedlands, Western Australia 6009, Australia
  • Local Institution - 0074
    Brussels, 1200, Belgium
  • Local Institution - 0065
    Leuven, 3000, Belgium
  • Local Institution - 0051
    Liège, 4000, Belgium
  • Local Institution
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • Local Institution
    São Paulo, São Paulo 04266-010, Brazil
  • Local Institution
    São Paulo, São Paulo 04520-013, Brazil
  • Local Institution - 0076
    São Paulo, 01323020, Brazil
  • Local Institution - 0141
    Vancouver, British Columbia V5Z 1M9, Canada
  • Local Institution
    Vancouver, British Columbia V5Z 1M9, Canada
  • Local Institution - 0134
    Toronto, Ontario M5T 3A9, Canada
  • Local Institution - 0094
    Montreal, Quebec H2X 3E4, Canada
  • Local Institution - 0127
    Québec, Quebec G1V 2G5, Canada
  • Local Institution - 0144
    Sherbrooke, Quebec J1H 5N4, Canada
  • Local Institution - 0108
    Curicó, Maule Region 3341643, Chile
  • Local Institution - 0054
    Talca, Maule Region 3481349, Chile
  • Local Institution - 0038
    Quillota, Valparaiso 0, Chile
  • Local Institution - 0187
    Beijing, Beijing Municipality 100020, China
  • Local Institution - 0183
    Beijing, Beijing Municipality 100730, China
  • Local Institution - 0188
    Wuhan, Hubei 430022, China
  • Local Institution - 0189
    Shanghai, Shanghai Municipality 200030, China
  • Local Institution - 0120
    Bobigny, 93000, France
  • Local Institution - 0066
    Bron, 69677, France
  • Local Institution - 0136
    Dijon, 21000, France
  • Local Institution - 0162
    Marseille, 13915, France
  • Hopital Europeen Georges Pompidou
    Paris, 75015, France
  • Local Institution - 0143
    Paris, 75018, France
  • Local Institution - 0067
    Rennes, 35033, France
  • Local Institution - 0132
    Toulouse, 31059, France
  • Local Institution - 0111
    Hanover, Lower Saxony 30459, Germany
  • Local Institution - 0107
    Essen, 45239, Germany
  • Local Institution
    Freiburg im Breisgau, 79106, Germany
  • Local Institution - 0093
    Großhansdorf, 22927, Germany
  • Local Institution - 0110
    Heidelberg, 69126, Germany
  • Local Institution - 0121
    Munich, 81377, Germany
  • Local Institution - 0119
    Stuttgart, 70736, Germany
  • Local Institution - 0145
    Tel Aviv, Tel Aviv 6423906, Israel
  • Local Institution - 0113
    Haifa, 34362, Israel
  • Local Institution - 0149
    Jerusalem, 9112001, Israel
  • Local Institution - 0114
    Petah Tikva, 4941492, Israel
  • Local Institution - 0148
    Ramat Gan, 5262100, Israel
  • Local Institution - 0073
    Catania, 95123, Italy
  • Local Institution - 0077
    Modena, 41125, Italy
  • Local Institution - 0089
    Monza, 20900, Italy
  • Local Institution - 0072
    Roma, 00168, Italy
  • Local Institution - 0155
    Seto, Aichi-ken 489-8642, Japan
  • Local Institution - 0106
    Kōriyama, Fukushima 963-0197, Japan
  • Local Institution - 0180
    Sapporo, Hokkaido 060-8543, Japan
  • Local Institution - 0095
    Kobe, Hyōgo 6500047, Japan
  • Local Institution - 0169
    Kobe, Hyōgo 653-0013, Japan
  • Local Institution - 0071
    Yokohama, Kanagawa 236-0051, Japan
  • Local Institution - 0112
    Sakai, Osaka 591-8555, Japan
  • Local Institution - 0128
    Izumo, Shimane 693-0021, Japan
  • Local Institution - 0064
    Hamamatasu, Shizuoka 431-3192, Japan
  • Local Institution - 0080
    Bunkyo-ku, Tokyo 113-8510, Japan
  • Local Institution - 0153
    Minato-ku, Tokyo 1058470, Japan
  • Local Institution - 0177
    Shinjyuku-ku, Tokyo 162-8655, Japan
  • Local Institution - 0117
    Kumamoto, 861-4193, Japan
  • Local Institution - 0146
    Nagasaki, 852-8102, Japan
  • Local Institution - 0170
    Saitama, 330-8553, Japan
  • Local Institution - 0173
    Tokyo, 143-8541, Japan
  • Local Institution
    Mexico City, Mexico City 06700, Mexico
  • Local Institution - 0081
    Monterrey, Nuevo León 64718, Mexico
  • Local Institution - 0109
    Monterrey, N.l., Nuevo León 64460, Mexico
  • Local Institution - 0083
    San Nicolás de los Garza, Nuevo León 66465, Mexico
  • Local Institution - 0156
    Oaxaca City, Oaxaca 68020, Mexico

Showing the first 100 of 119 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kreuter M, Maher TM, Wuyts WA, Valenzuela C, Hamblin M, Kim S, Patel A, Elpers B, Richeldi L. Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis. Chest. 2025 Sep;168(3):677-687. doi: 10.1016/j.chest.2025.04.003. Epub 2025 Apr 8. PubMed 40210090 ↗
  • Corte TJ, Behr J, Cottin V, Glassberg MK, Kreuter M, Martinez FJ, Ogura T, Suda T, Wijsenbeek M, Berkowitz E, Elpers B, Kim S, Watanabe H, Fischer A, Maher TM. Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. Am J Respir Crit Care Med. 2025 Feb;211(2):230-238. doi: 10.1164/rccm.202405-0977OC. PubMed 39393084 ↗
  • Corte TJ, Lancaster L, Swigris JJ, Maher TM, Goldin JG, Palmer SM, Suda T, Ogura T, Minnich A, Zhan X, Tirucherai GS, Elpers B, Xiao H, Watanabe H, Smith RA, Charles ED, Fischer A. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respir Res. 2021 Dec;8(1):e001026. doi: 10.1136/bmjresp-2021-001026. PubMed 34969771 ↗
  • Cheng PTW, Kaltenbach RF 3rd, Zhang H, Shi J, Tao S, Li J, Kennedy LJ, Walker SJ, Shi Y, Wang Y, Dhanusu S, Reddigunta R, Kumaravel S, Jusuf S, Smith D, Krishnananthan S, Li J, Wang T, Heiry R, Sum CS, Kalinowski SS, Hung CP, Chu CH, Azzara AV, Ziegler M, Burns L, Zinker BA, Boehm S, Taylor J, Sapuppo J, Mosure K, Everlof G, Guarino V, Zhang L, Yang Y, Ruan Q, Xu C, Apedo A, Traeger SC, Cvijic ME, Lentz KA, Tirucherai G, Sivaraman L, Robl J, Ellsworth BA, Rosen G, Gordon DA, Soars MG, Gill M, Murphy BJ. Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases. J Med Chem. 2021 Nov 11;64(21):15549-15581. doi: 10.1021/acs.jmedchem.1c01256. Epub 2021 Oct 28. PubMed 34709814 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Aug 2022, 24 months.

Results were first posted in Feb 2025, 2 years 6 months after primary completion. A results delay was requested in Jul 2023.

Of 33 phase 2 interventional studies under Pulmonary Fibrosis, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 75. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2020
First posted
Mar 16, 2020
StartActual
Jul 29, 2020
Primary completionActual
Aug 4, 2022
CompletionActual
Sep 22, 2023
Results delay requested
Jul 26, 2023
Results first posted
Feb 24, 2025
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04308681
Responsible party
Sponsor
First posted
Mar 16, 2020
Start date
Jul 29, 2020
Primary completion
Aug 4, 2022
Completion
Sep 22, 2023
Results posted
Feb 24, 2025
Last update
Feb 3, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Admilparant

Start the discussion